BioAge Labs, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.bioagelabs.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared With Tirzepatide Alone in Participants With Obesity Aged 55 Years and Over
- Conditions
- Obesity
- Interventions
- Drug: Oral Azelaprag (BGE-105)Drug: Oral Placebo for Azelaprag (BGE-105)
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- BioAge Labs, Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT06515418
- Locations
- 🇺🇸
Site 110, Mesa, Arizona, United States
🇺🇸Site 107, Los Angeles, California, United States
🇺🇸Site 103, Montclair, California, United States
Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- BioAge Labs, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06141889
- Locations
- 🇳🇿
New Zealand Clinical Research, Auckland, New Zealand
Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery
- Conditions
- Acute Posthemorrhagic Anemia
- Interventions
- Drug: BGE-117, 4mgDietary Supplement: Ferrous SulfateOther: Matching PlaceboDrug: BGE-117, 12mg
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- BioAge Labs, Inc.
- Registration Number
- NCT05152641
- Locations
- 🇦🇺
Renal Research, Gosford, New South Wales, Australia
Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- BioAge Labs, Inc.
- Registration Number
- NCT04815603
- Locations
- 🇦🇺
Paratus Clinical Research - Western Sydney, Blacktown, New South Wales, Australia
🇦🇺Emeritus Research Sydney, Botany, New South Wales, Australia
🇦🇺Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- BioAge Labs, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT04705597
- Locations
- 🇺🇸
Banner Health, Mesa, Arizona, United States
🇺🇸Velocity Clinical Research, Chula Vista, Chula Vista, California, United States
🇺🇸Long Beach Medical Center, Long Beach, California, United States